Largent Health Receives FDA Clearance for FiteBac® Cavity Cleanser

Friday, January 24, 2020 Dental News
Email Print This Page Comment bookmark
Font : A-A+

FiteBac® Cavity Cleanser can not only remove debris in carious lesion preparations but can penetrate exposed dentin tubules allowing restorative adhesives to tightly bind to the prepared dentin surface.

MARIETTA, Ga., Jan. 23, 2020 /PRNewswire-PRWeb/ -- FiteBac® Cavity Cleanser can not only remove debris in carious lesion preparations but can penetrate exposed dentin tubules allowing restorative adhesives to tightly bind to the prepared dentin surface.

Largent Health, LLC announced today receipt of FDA clearance to market FiteBac® Cavity Cleanser with 2% K21. Cavity cleansers are intended for cleansing and moistening/re-wetting of prepared dental surfaces prior to completing a restoration.

Largent Health is a company dedicated to bringing innovative antimicrobial technology to healthcare products. "The clearance of Largent Health's FiteBac® Cavity Cleanser represents the second FDA regulatory clearance of our FiteBac® technology and the first for our K21 molecule" said Kirk Kimmerling, DDS, Founder and CEO of Kimmerling Holdings Group.

FiteBac® Cavity Cleanser, with 2% K21, is intended to become part of the restoration/dentin interface by copolymerizing with the dental adhesive. Research shows FiteBac® Cavity Cleanser can not only remove debris in carious lesion preparations but also penetrates exposed dentin tubules allowing restorative adhesives to tightly bind to the prepared dentin surface. Published research supports that a 2% K21 solution is significantly less cytotoxic on human dentin pulp cells than 2% chlorhexidine gluconate, a common component in other cavity cleanser and dental preparations.

"Receipt of our first medical device clearance from FDA represents a significant step forward for all of us at Largent Health and would not have been possible without the efforts of our collaborators and partners, both here in the U.S. as well as overseas.," commented John W. Sharkey, Ph.D., CEO of Largent Health LLC. "With the potential for low cytotoxicity and the ability to promote strong binding of adhesives systems to dentin , we believe FiteBac® Cavity Cleanser will become the preferred cavity cleanser for the dental professional."

To learn more about how FiteBac® technology is being developed for dental applications please visit http://www.FiteBacDental.com.

 

SOURCE Largent Health LLC



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Premium Membership Benefits

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store